FORBES-TATE

Lobbying for ULTRAGENYX PHARMACEUTICAL · Clinical-state biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $30,000.00 income · posted Jul 20, 2026

Lobbying activity 1

Health Issues

Issues related to drug development and market access.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem